Literature DB >> 2254023

Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II.

E A Wadolkowski1, L M Sung, J A Burris, J E Samuel, A D O'Brien.   

Abstract

Escherichia coli O157:H7 strains have been implicated as etiologic agents in food-borne outbreaks of hemorrhagic colitis and the hemolytic-uremic syndrome. A prototype E. coli O157:H7 strain, designated 933, produces Shiga-like toxin I (SLT-I) and SLT-II and harbors a 60-MDa plasmid. In a previous study, streptomycin-treated mice were fed 933 together with a derivative cured of the 60-MDa plasmid (designated 933cu). Strain 933cu colonized poorly, but in approximately one-third of the animals, an isolate of 933cu was obtained from the feces that had regained the ability to colonize well. This isolate, designated 933cu-rev, killed all of the animals when fed alone to mice. In this investigation, two types of experiments were done to assess whether SLT-I, SLT-II, or both contributed to the death of mice fed 933cu-rev. (i) Mice were pretreated with monoclonal antibodies to SLT-I, SLT-II, SLT-I and SLT-II, or cholera toxin (as a control) before infection with 933cu-rev. (ii) Mice were fed either an E. coli K-12 strain carrying cloned SLT-I genes or the same K-12 strain carrying cloned SLT-II genes. The results of both types of experiments indicated that the deaths of the orally infected mice were due solely to SLT-II. Extensive histological and selected electron microscopic examinations of various tissues from the infected animals suggested that death was due to acute renal cortical tubular necrosis consistent with toxic renal damage. These data indicate a critical role for SLT-II, but not SLT-I, in renal damage associated with E. coli O157:H7 infection of streptomycin-treated mice.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2254023      PMCID: PMC313762          DOI: 10.1128/iai.58.12.3959-3965.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

1.  Cloning of genes for production of Escherichia coli Shiga-like toxin type II.

Authors:  J W Newland; N A Strockbine; R J Neill
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

2.  Mouse model for colonization and disease caused by enterohemorrhagic Escherichia coli O157:H7.

Authors:  E A Wadolkowski; J A Burris; A D O'Brien
Journal:  Infect Immun       Date:  1990-08       Impact factor: 3.441

3.  Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins.

Authors:  Y Endo; K Tsurugi; T Yutsudo; Y Takeda; T Ogasawara; K Igarashi
Journal:  Eur J Biochem       Date:  1988-01-15

4.  Globotriosyl ceramide is specifically recognized by the Escherichia coli verocytotoxin 2.

Authors:  T Waddell; S Head; M Petric; A Cohen; C Lingwood
Journal:  Biochem Biophys Res Commun       Date:  1988-04-29       Impact factor: 3.575

5.  The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections.

Authors:  S E Richardson; M A Karmali; L E Becker; C R Smith
Journal:  Hum Pathol       Date:  1988-09       Impact factor: 3.466

6.  Cloning and sequencing of a Shiga-like toxin type II variant from Escherichia coli strain responsible for edema disease of swine.

Authors:  D L Weinstein; M P Jackson; J E Samuel; R K Holmes; A D O'Brien
Journal:  J Bacteriol       Date:  1988-09       Impact factor: 3.490

7.  Anticytotoxin-neutralizing antibodies in immune globulin preparations: potential use in hemolytic-uremic syndrome.

Authors:  S Ashkenazi; T G Cleary; E Lopez; L K Pickering
Journal:  J Pediatr       Date:  1988-12       Impact factor: 4.406

8.  Isolation and characterization of monoclonal antibodies to Shiga-like toxin II of enterohemorrhagic Escherichia coli and use of the monoclonal antibodies in a colony enzyme-linked immunosorbent assay.

Authors:  L P Perera; L R Marques; A D O'Brien
Journal:  J Clin Microbiol       Date:  1988-10       Impact factor: 5.948

9.  Affinity purification and characterization of Shiga-like toxin II and production of toxin-specific monoclonal antibodies.

Authors:  F P Downes; T J Barrett; J H Green; C H Aloisio; J S Spika; N A Strockbine; I K Wachsmuth
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

10.  Cloning and sequencing of the genes for Shiga toxin from Shigella dysenteriae type 1.

Authors:  N A Strockbine; M P Jackson; L M Sung; R K Holmes; A D O'Brien
Journal:  J Bacteriol       Date:  1988-03       Impact factor: 3.490

View more
  82 in total

1.  Shiga toxins 1 and 2 translocate differently across polarized intestinal epithelial cells.

Authors:  B P Hurley; M Jacewicz; C M Thorpe; L L Lincicome; A J King; G T Keusch; D W Acheson
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

2.  Isogenic lysogens of diverse shiga toxin 2-encoding bacteriophages produce markedly different amounts of shiga toxin.

Authors:  P L Wagner; D W Acheson; M K Waldor
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

Review 3.  Bacteriophage control of bacterial virulence.

Authors:  Patrick L Wagner; Matthew K Waldor
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

4.  Bacterial ghosts as an oral vaccine: a single dose of Escherichia coli O157:H7 bacterial ghosts protects mice against lethal challenge.

Authors:  Ulrike Beate Mayr; Christoph Haller; Wolfgang Haidinger; Alena Atrasheuskaya; Eugenij Bukin; Werner Lubitz; Georgy Ignatyev
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

5.  Monocyte chemoattractant protein 1, macrophage inflammatory protein 1 alpha, and RANTES recruit macrophages to the kidney in a mouse model of hemolytic-uremic syndrome.

Authors:  Tiffany R Keepers; Lisa K Gross; Tom G Obrig
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

6.  Neutralizing antibodies to Shiga toxin type 2 (Stx2) reduce colonization of mice by Stx2-expressing Escherichia coli O157:H7.

Authors:  Krystle L Mohawk; Angela R Melton-Celsa; Cory M Robinson; Alison D O'Brien
Journal:  Vaccine       Date:  2010-05-14       Impact factor: 3.641

7.  Direct evidence of neuron impairment by oral infection with verotoxin-producing Escherichia coli O157:H- in mitomycin-treated mice.

Authors:  J Fujii; T Kita; S Yoshida; T Takeda; H Kobayashi; N Tanaka; K Ohsato; Y Mizuguchi
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

8.  Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans.

Authors:  P Boerlin; S A McEwen; F Boerlin-Petzold; J B Wilson; R P Johnson; C L Gyles
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

9.  Non-O157:H7 Stx2-producing Escherichia coli strains associated with sporadic cases of hemolytic-uremic syndrome in adults.

Authors:  R Bonnet; B Souweine; G Gauthier; C Rich; V Livrelli; J Sirot; B Joly; C Forestier
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

10.  The specific activities of Shiga-like toxin type II (SLT-II) and SLT-II-related toxins of enterohemorrhagic Escherichia coli differ when measured by Vero cell cytotoxicity but not by mouse lethality.

Authors:  S W Lindgren; J E Samuel; C K Schmitt; A D O'Brien
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.